118 related articles for article (PubMed ID: 17666312)
1. Differences of nine drug resistance interpretation systems in predicting short-term therapy outcomes of treatment-experienced HIV-1 infected patients: a retrospective observational cohort study.
Helm M; Walter H; Ehret R; Schmit JC; Kurowski M; Knechten H; Korn K; Braun P; Schmidt B
Eur J Med Res; 2007 Jun; 12(6):231-42. PubMed ID: 17666312
[TBL] [Abstract][Full Text] [Related]
2. A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients.
Van Laethem K; De Luca A; Antinori A; Cingolani A; Perna CF; Vandamme AM
Antivir Ther; 2002 Jun; 7(2):123-9. PubMed ID: 12212924
[TBL] [Abstract][Full Text] [Related]
3. Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes.
De Luca A; Vendittelli M; Baldini F; Di Giambenedetto S; Trotta MP; Cingolani A; Bacarelli A; Gori C; Perno CF; Antinori A; Ulivi G
Antivir Ther; 2004 Aug; 9(4):583-93. PubMed ID: 15456090
[TBL] [Abstract][Full Text] [Related]
4. Virologic therapy response significantly correlates with the number of active drugs as evaluated using a LiPA HIV-1 resistance scoring system.
Ziermann R; Celis L; Derdelinckx I; Lambert C; Veeck J; Rizzo MG; Vanderborght B; Zissis G; Clumeck N; Fransen K; Vaira D; Hendricks D; Van Laethem K; Vandamme AM; Schmit JC; Knechten H; De Luca A; Louwagie J; Segers P; De Boeck K; Pottel H; De Brauwer A; Hulstaert F
J Clin Virol; 2004 Dec; 31 Suppl 1():S7-15. PubMed ID: 15567089
[TBL] [Abstract][Full Text] [Related]
5. Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting.
Zazzi M; Prosperi M; Vicenti I; Di Giambenedetto S; Callegaro A; Bruzzone B; Baldanti F; Gonnelli A; Boeri E; Paolini E; Rusconi S; Giacometti A; Maggiolo F; Menzo S; De Luca A;
J Antimicrob Chemother; 2009 Sep; 64(3):616-24. PubMed ID: 19620134
[TBL] [Abstract][Full Text] [Related]
6. Variability in the interpretation of transmitted genotypic HIV-1 drug resistance and prediction of virological outcomes of the initial HAART by distinct systems.
De Luca A; Cozzi-Lepri A; Perno CF; Balotta C; Di Giambenedetto S; Poggio A; Pagano G; Tositti G; Piscopo R; Del Forno A; Chiodo F; Magnani G; d'Arminio Monforte A; ;
Antivir Ther; 2004 Oct; 9(5):743-52. PubMed ID: 15535412
[TBL] [Abstract][Full Text] [Related]
7. A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy.
Wang D; Larder B; Revell A; Montaner J; Harrigan R; De Wolf F; Lange J; Wegner S; Ruiz L; Pérez-Elías MJ; Emery S; Gatell J; D'Arminio Monforte A; Torti C; Zazzi M; Lane C
Artif Intell Med; 2009 Sep; 47(1):63-74. PubMed ID: 19524413
[TBL] [Abstract][Full Text] [Related]
8. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
Cozzi-Lepri A; Phillips AN; Clotet B; Mocroft A; Ruiz L; Kirk O; Lazzarin A; Wiercinska-Drapalo A; Karlsson A; Lundgren JD;
AIDS; 2008 Oct; 22(16):2187-98. PubMed ID: 18832882
[TBL] [Abstract][Full Text] [Related]
9. Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment.
Prosperi MC; Altmann A; Rosen-Zvi M; Aharoni E; Borgulya G; Bazso F; Sönnerborg A; Schülter E; Struck D; Ulivi G; Vandamme AM; Vercauteren J; Zazzi M;
Antivir Ther; 2009; 14(3):433-42. PubMed ID: 19474477
[TBL] [Abstract][Full Text] [Related]
10. Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response.
Assoumou L; Brun-Vézinet F; Cozzi-Lepri A; Kuritzkes D; Phillips A; Zolopa A; Degruttola V; Miller V; Costagliola D;
J Infect Dis; 2008 Aug; 198(4):470-80. PubMed ID: 18598191
[TBL] [Abstract][Full Text] [Related]
11. Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network.
Chaix ML; Desquilbet L; Descamps D; Costagliola D; Deveau C; Galimand J; Goujard C; Signori-Schmuck A; Schneider V; Tamalet C; Pellegrin I; Wirden M; Masquelier B; Brun-Vezinet F; Rouzioux C; Meyer L; ;
Antivir Ther; 2007; 12(8):1305-10. PubMed ID: 18240870
[TBL] [Abstract][Full Text] [Related]
12. The development of artificial neural networks to predict virological response to combination HIV therapy.
Larder B; Wang D; Revell A; Montaner J; Harrigan R; De Wolf F; Lange J; Wegner S; Ruiz L; Pérez-Elías MJ; Emery S; Gatell J; Monforte AD; Torti C; Zazzi M; Lane C
Antivir Ther; 2007; 12(1):15-24. PubMed ID: 17503743
[TBL] [Abstract][Full Text] [Related]
13. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure.
Spudich S; Lollo N; Liegler T; Deeks SG; Price RW
J Infect Dis; 2006 Dec; 194(12):1686-96. PubMed ID: 17109340
[TBL] [Abstract][Full Text] [Related]
14. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.
Bergroth T; Ekici H; Gisslén M; Loes SK; Goh LE; Freedman A; Lampe F; Johnson MA; Sönnerborg A
J Med Virol; 2009 Jan; 81(1):1-8. PubMed ID: 19031460
[TBL] [Abstract][Full Text] [Related]
15. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
16. Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure.
Lohse N; Jørgensen LB; Kronborg G; Møller A; Kvinesdal B; Sørensen HT; Obel N; Gerstoft J;
Antivir Ther; 2007; 12(6):909-17. PubMed ID: 17926645
[TBL] [Abstract][Full Text] [Related]
17. Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome.
García-Gascó P; Maida I; Blanco F; Barreiro P; Martín-Carbonero L; Vispo E; González-Lahoz J; Soriano V
J Antimicrob Chemother; 2008 Mar; 61(3):699-704. PubMed ID: 18192682
[TBL] [Abstract][Full Text] [Related]
18. The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors.
Fox ZV; Geretti AM; Kjaer J; Dragsted UB; Phillips AN; Gerstoft J; Staszewski S; Clotet B; von Wyl V; Lundgren JD
AIDS; 2007 Oct; 21(15):2033-42. PubMed ID: 17885293
[TBL] [Abstract][Full Text] [Related]
19. Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study.
Di Giambenedetto S; Bracciale L; Colafigli M; Cattani P; Pinnetti C; Bacarelli A; Prosperi M; Fadda G; Cauda R; De Luca A
Antivir Ther; 2007; 12(5):835-9. PubMed ID: 17713168
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice.
Fabbiani M; Di Giambenedetto S; Bracciale L; Bacarelli A; Ragazzoni E; Cauda R; Navarra P; De Luca A
J Antimicrob Chemother; 2009 Jul; 64(1):109-17. PubMed ID: 19398461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
